# Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

> **NCT04768075** · PHASE3 · UNKNOWN · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 200 (estimated)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Placebo
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Albumin paclitaxel

## Key facts

- **NCT ID:** NCT04768075
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-05
- **Primary completion:** 2022-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04768075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04768075, "Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04768075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*